Aclaris Therapeutics (ACRS) Short term Debt (2017 - 2022)
Aclaris Therapeutics (ACRS) posted quarterly Short term Debt of $2.7 million for Q3 2022, down 12.2% year-over-year from $3.1 million in Q3 2021, and little changed quarter-over-quarter from $2.7 million in Q2 2022.
Aclaris Therapeutics (ACRS) Short term Debt (2017 - 2022) Analysis & Trends
Aclaris Therapeutics' Short term Debt history runs 3 years deep, the most recent figure standing at $2.7 million for Q3 2022.
- In Q3 2022, Short term Debt fell 12.2% year-over-year to $2.7 million; the TTM figure through Sep 2022 stood at $2.7 million (down 12.2% YoY), while the FY2021 annual figure was $2.6 million, changed N/A from the prior year.
- Short term Debt for Q3 2022 stood at $2.7 million, roughly flat from $2.7 million in the prior quarter.
- The five-year high for Short term Debt was $3.1 million in Q2 2021, with the low at $2.6 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 2.70 Mn |
| Jun 30, 2022 | 2.70 Mn |
| Mar 31, 2022 | 2.70 Mn |
| Dec 31, 2021 | 2.65 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 3.08 Mn |
| Dec 31, 2017 | 590,000.00 |